Nonsynchronous Rotation Evidence and Fracture History in the Bright Plains Region, Europa

Icarus ◽  
2002 ◽  
Vol 157 (2) ◽  
pp. 490-506 ◽  
Author(s):  
Simon A. Kattenhorn
Keyword(s):  
Fracture History ◽  
Nonsynchronous Rotation

Rationale, baseline characteristics and methodology of the non-interventional VIVA study in postmenopausal osteoporosis

2014 ◽  
Vol 23 (01) ◽  
pp. 49-55
Author(s):  
L. C. Hofbauer ◽  
D. Felsenberg ◽  
M. Amling ◽  
A. Kurth ◽  
P. Hadji
Keyword(s):  
Quality Of Life ◽  
Postmenopausal Osteoporosis ◽  
Primary Outcome ◽  
Osteoporosis Treatment ◽  
Secondary Outcome ◽  
Matched Pairs ◽  
Fracture History ◽  
Baseline Characteristics ◽  
Study Inclusion

SummaryIt is important to understand compliance and persistence with medication use in the clinical practice of osteoporosis treatment. The purpose of this work is to describe the “intravenous ibandronate versus oral alendronate” (VIVA) study, a non-interventional trial to assess the compliance and persistence of osteopenic postmenopausal women with treatment via weekly oral alendronate or intravenous ibandronate (Bonviva®) every three months.4477 patients receiving ibandronate 3 mg i. v. quarterly and 1491 patients receiving alendronate 70 mg orally weekly were included in the study. Matched pairs of 901 subjects in each group were also generated. Matching was performed on the basis of age, body mass index, fracture history at study inclusion, prior treatment with bisphosphonates and the number of concomitant disorders. Secondary outcome measures of osteoporosis related fractures, mobility restriction and pain, analgesia, quality of life questionnaires as well as attitudes to medications were assessed. The primary outcome parameters of compliance and persistence will be tracked in these subjects.At baseline, the entire collectives differed significantly on body weight (less in ibandronate group), duration since osteo - porosis diagnosis (longer in ibandronate), and incidence of prior osteoporotic fracture (higher in ibandronate group). The matched-pairs differed only on mobility restriction and quality of life (both worse in ibandronate group).The results from the VIVA study trial will provide scientific rationale for clinical recommendations in the pharmacological treatment of postmenopausal osteoporosis.

Physical Inactivity and Pain in Older Men and Women with Hip Fracture History

Gerontology ◽  
2011 ◽  
Vol 57 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Anu Salpakoski ◽  
Erja Portegijs ◽  
Mauri Kallinen ◽  
Sanna Sihvonen ◽  
Ilkka Kiviranta ◽  
...  
Keyword(s):  
Hip Fracture ◽  
Physical Inactivity ◽  
Older Men ◽  
Men And Women ◽  
Fracture History ◽  
Older Men And Women

Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius

Bone ◽  
2013 ◽  
Vol 55 (2) ◽  
pp. 377-383 ◽  
Author(s):  
T. Chevalley ◽  
J.P. Bonjour ◽  
B. van Rietbergen ◽  
S. Ferrari ◽  
R. Rizzoli
Keyword(s):  
Distal Radius ◽  
Premenopausal Women ◽  
History Of ◽  
Fracture History

scholarly journals AB1206 SELF-REPORT OF FRACTURE HISTORY COMPARED TO FRACTURE CODES FROM AN ELECTRONIC HEALTH RECORD DATASET

2019 ◽  
Author(s):  
Maria Danila ◽  
Amy Mudano ◽  
Elizabeth Rahn ◽  
Andrea Lacroix ◽  
Jeffrey Curtis ◽  
...  
Keyword(s):  
Electronic Health Record ◽  
Self Report ◽  
Health Record ◽  
Fracture History ◽  
Electronic Health

scholarly journals Increased Burden of Common Risk Alleles in Children With a Significant Fracture History

2020 ◽  
Vol 35 (5) ◽  
pp. 875-882 ◽  
Author(s):  
Despoina Manousaki ◽  
Anders Kämpe ◽  
Vincenzo Forgetta ◽  
Riikka E Makitie ◽  
Ghalib Bardai ◽  
...  
Keyword(s):  
Risk Alleles ◽  
Fracture History

scholarly journals Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Joan C. Lo ◽  
Romain S. Neugebauer ◽  
Bruce Ettinger ◽  
Malini Chandra ◽  
Rita L. Hui ◽  
...  
Keyword(s):  
Cumulative Incidence ◽  
Femur Fracture ◽  
Demographic Data ◽  
Large Population ◽  
Risk Difference ◽  
Atypical Femur Fracture ◽  
Oral Bisphosphonate ◽  
Increased Risk ◽  
Incidence Risk ◽  
Fracture History

Abstract Background Bisphosphonate (BP) therapy has been associated with atypical femur fracture (AFF). However, the threshold of treatment duration leading to increased AFF risk is unclear. In a retrospective cohort of older women initiating BP, we compared the AFF risk associated with treatment for at least three years to the risk associated with treatment less than three years. Methods We used observational data from a large population of female members of an integrated healthcare system who initiated oral BP during 2002–2014. Women were retrospectively followed for incident AFF confirmed by radiologic adjudication. Demographic data, pharmacologic exposures, comorbidity, bone density, and fracture history were ascertained from electronic health records. Inverse probability weighting was used to estimate risk differences comparing the cumulative incidence (risk) of AFF if women discontinued BP within three years to the cumulative incidence of AFF if women continued BP for three or more years, adjusting for potential time-dependent confounding by the aforementioned factors. Results Among 87,820 women age 45–84 years who initiated BP (mean age 68.6, median T-score − 2.6, 14% with prior major osteoporotic fracture), 16,180 continued BP for three or more years. Forty-six confirmed AFFs occurred during follow-up in the two groups. AFF-free survival was greater for BP treatment < 3 years compared to treatment ≥3 years (p = 0.004 comparing areas under survival curves). At five years, the risk of AFF was 27 per 100,000 (95% confidence interval, CI: 8–46) if women received BP treatment < 3 years and 120 per 100,000 (95% CI: 56–183) if women received BP treatment ≥3 years (risk difference 93 per 100,000, 95% CI: 30–160). By ten years, the risks were 27 (95% CI: 8–46) and 363 (95% CI: 132–593) per 100,000 for BP treatment < 3 and ≥ 3 years, respectively (risk difference 336 per 100,000, 95% CI: 110–570). Conclusions Bisphosphonate treatment for 3 or more years was associated with greater risk of AFF than treatment for less than 3 years. Although AFFs are uncommon among BP-treated women, this increased risk should be considered when counseling women about long-term BP use. Future studies should further characterize the dose-response relationship between BP duration and incident AFF and identify patients at highest risk.

Iron Overload Associated Endocrine Dysfunction Leading to Lower Bone Mineral Density in Thalassemia Major

2020 ◽  
Vol 105 (4) ◽  
pp. e1015-e1024
Author(s):  
Wen-Ping Yang ◽  
Hsiu-Hao Chang ◽  
Hung-Yuan Li ◽  
Ying-Chuen Lai ◽  
Tse-Ying Huang ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Iron Overload ◽  
Bone Mineral ◽  
Fibroblast Growth Factor 23 ◽  
Body Height ◽  
Thalassemia Major ◽  
Lower Bone Mineral Density ◽  
Mineral Density ◽  
Fracture History ◽  
The Mean

Abstract Context Patients with thalassemia major (TM) have a lower bone mineral density (BMD) and higher risk of fracture than the general population. The possible mechanisms include anemia, iron overload, malnutrition, and hormonal deficiency, but these have not been thoroughly investigated. Objective To identify major mineral and hormonal factors related to BMD in adult TM patients to provide human evidence for the proposed mechanisms. Design Retrospective study. Setting Referral center. Patients Twenty-nine patients with β-TM, aged 23 to 44 years who were followed-up during 2017 to 2018 were enrolled. Outcome measurements Endocrine profiles, including thyroid, parathyroid, and pituitary function, glucose, vitamin D, calcium, phosphate, and fibroblast growth factor 23 (FGF23) were obtained. The relationships among the above parameters, body height, fractures, and BMD were analyzed. Results Abnormal BMD was observed in 42.9% of women and 23.1% of men. The mean final heights of women and men were 3.7 cm and 7.3 cm lower than the mean expected values, respectively. Fracture history was recorded in 26.7% of women and 35.7% of men. BMD was negatively correlated with parathyroid hormone, FGF23, thyrotropin, and glycated hemoglobin (HbA1c) levels, and positively correlated with testosterone, IGF-1, and corticotropin levels (all P &lt; .05). Moreover, hypothyroidism was associated with lower BMD in both the lumbar spine (P = .024) and the femoral neck (P = .004). Patients with hypothyroidism had a higher percentage of abnormal BMD (P = .016). Conclusion Hypothyroidism, higher HbA1c, and lower adrenocorticotropin were predictors of abnormal BMD in patients with β-TM. Whether the correction of these factors improves BMD warrants further research.

scholarly journals Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS)

2019 ◽  
Vol 59 (1) ◽  
Author(s):  
Joao L. Cunha-Borges ◽  
Guillermo Meléndez Mier ◽  
Noemí Casas ◽  
Adriana Medina ◽  
Jose Fernando Molina ◽  
...  
Keyword(s):  
Latin America ◽  
Observational Study ◽  
Postmenopausal Women ◽  
Latin American ◽  
Real World Setting ◽  
Related Quality ◽  
Health Related ◽  
History Of ◽  
Fracture History

Abstract Background Osteoporosis is a major healthcare concern in Latin America. Factors such as changing demographics, fragmented healthcare systems, and financial considerations may result in a huge increase in the burden of osteoporosis in this region. The aim of this article is to describe the baseline clinical characteristics and fracture history of patients who are prescribed teriparatide in normal clinical practice in Latin America. Methods We conducted a prospective, multinational, observational study (the Asia and Latin America Fracture Observational Study [ALAFOS]) in 20 countries worldwide to assess the incidence of fractures in postmenopausal women with osteoporosis receiving teriparatide as a part of routine clinical practice in a real-world setting. In this subregional analysis of the ALAFOS study, we report the clinical characteristics, fracture history, risk factors for osteoporosis, comorbidities, previous osteoporosis therapies and health-related quality of life measures at baseline for patients from the four participant Latin American countries: Argentina, Brazil, Colombia, and Mexico. Results The Latin America subregional cohort included 546 postmenopausal women (mean [SD] age: 71.0 [10.1] years; range: 40–94 years), constituting 18% of the ALAFOS total population. The baseline mean (SD) bone mineral density T-scores were − 3.02 (1.23) at the lumbar spine and − 2.31 (0.96) at the femoral neck; 62.8% of patients had a history of low trauma fracture after the age of 40 years and 39.7% of patients had experienced ≥1 fall in the past year. Osteoporosis medications were used by 70.9% of patients before initiating teriparatide. The median (Q1, Q3) EQ-5D-5 L Visual Analog Scale (VAS) scores for perceived health status at baseline was 70 (50, 80). The mean (SD) worst back pain numeric rating scale score for the overall Latin American cohort was 4.3 (3.4) at baseline. Conclusions This baseline analysis of the Latin America subregion of the ALAFOS study indicates that patients who are prescribed teriparatide in the four participant countries had severe osteoporosis and high prevalence of fractures. They also had back pain and poor health-related quality of life. The proportions of patients with severe or extreme problems on the EQ-5D-5 L individual domains were lower than those in the overall ALAFOS study population.

Sign in / Sign up

Export Citation Format

Share Document